Results 21 to 30 of about 539 (92)

Mapping of C5‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition

Immunology, EarlyView.
We identify four distinct C5 inhibitory epitopes, including two novel antibodies that selectively block membrane attack complex (MAC) assembly while preserving C5 cleavage and C5a generation. These findings establish selective MAC inhibition as a new therapeutic strategy for complement‐mediated diseases.
Rebekah Sian Cooke, Kok Yung Lee, Georgina Elizabeth Menzies, Masashi Mizuno, Bryan Paul Morgan, Wioleta Milena Zelek   +5 more
wiley   +1 more source

Artificial Intelligence Integration With Nanotechnology for Cancer Therapy

MedComm, Volume 7, Issue 9, September 2026.
AI‐enabled nanotechnology provides a continuous learning framework for cancer therapy by integrating nanomaterial design, biological interactions, tumor delivery, clinical data, and therapeutic feedback to support predictive design, patient‐aware optimization, and improved translational decision‐making.
Shengbin Liu, Zhi Liu, Haixing Shi, Chengyi Wei, Ruijie Zhang, Xiangrong Song   +5 more
wiley   +1 more source

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest

Pharmaceuticals
A total of nine TIDES (pepTIDES and oligonucleoTIDES) were approved by the FDA during 2023. The four approved oligonucleotides are indicated for various types of disorders, including amyotrophic lateral sclerosis, geographic atrophy, primary ...
Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, Beatriz G. de la Torre   +3 more
doaj   +1 more source

Advancing Treatment of Degenerative Eye Diseases at the Nanoscale

Smart Medicine, Volume 5, Issue 4, August 2026.
Nanotherapeutics possess the potential to overcome longstanding bottlenecks in treating degenerative ophthalmic diseases. With a highly tunable surface chemistry, nanotechnology platforms can be customized to navigate specific anatomical barriers in the eye and target pathways of diseases.
Li Yao Jin, Evashiniee G. P. Selvam, Qinsong Mei, Chi D. Luu, Yeannie H. Y. Yap, Daniel B. L. Teh   +5 more
wiley   +1 more source

Dry Age-related Macular Degeneration: Not So Dry Today!!

Delhi Journal of Ophthalmology
Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in people over 55 years, driven by age-related changes in the retinal pigment epithelium, Bruch’s membrane, and choriocapillaris that impair waste clearance and
Bhanu Priya, Lalit Verma, Priksha Lakhlan, Avnindra Gupta   +3 more
doaj   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies

Advanced Healthcare Materials, Volume 15, Issue 23, 19 June 2026.
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best, Gizem Karabiyik, Gerd Geerling, Sarah Barbara Zwingelberg, Gregor Lang, Martin Humenik   +5 more
wiley   +1 more source

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology

International Journal of Nanomedicine, 2023
Jiamin Cao, Feng Zhang, Wei Xiong Department of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha, People’s Republic of ChinaCorrespondence: Feng Zhang; Wei Xiong, Department of Ophthalmology, the Third Xiangya Hospital, Central ...
Cao J, Zhang F, Xiong W
doaj  

The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy

Pharmaceutics
In addition to classic small-molecule drugs and modern protein-based biologics, an intriguing class of medicines is the therapeutic oligonucleotides. Most approved drugs in this category are antisense oligomers or those acting via RNA interference, both ...
Miklós Bege, Rasha Ghanem Kattoub, Anikó Borbás   +2 more
doaj   +1 more source

PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration

Pharmaceuticals
The alternative pathway of the complement system is implicated in the etiology of age-related macular degeneration (AMD). Complement depletion with pegcetacoplan and avacincaptad pegol are FDA-approved treatments for geographic atrophy in AMD that, while
Sheri L. Peterson, Anitha Krishnan, Diyan Patel, Ali Khanehzar, Amit Lad, Jutamas Shaughnessy, Sanjay Ram, David Callanan, Derek Kunimoto, Mohamed A. Genead, Michael J. Tolentino   +10 more
doaj   +1 more source